Jun 18 |
U.S. FDA Approves SKYRIZI® (risankizumab-rzaa) for Ulcerative Colitis, Expanding AbbVie's Portfolio Across Inflammatory Bowel Disease
|
Jun 18 |
AbbVie: 5 Reasons That Make A Buy Case
|
Jun 18 |
Intra-Cellular Therapies edges closer to FDA win for Caplyta in depression
|
Jun 18 |
Mustang (MBIO) Soars 477% on Data From Rare Blood Cancer Study
|
Jun 18 |
Humira: the highs and lows of the world’s best-selling drug
|
Jun 16 |
2 Dividend Stocks That Could Pay You for Life
|
Jun 15 |
ALS therapy market seen increasing to nearly $1.3B by 2029
|
Jun 14 |
AbbVie urges shareholders to reject mini-tender offer
|
Jun 14 |
AbbVie Recommends Shareholders Reject Tutanota's "Mini-Tender" Offer
|
Jun 14 |
Pharma Stock Roundup: FDA Panel Endorses LLY's Donanemab, PFE's DMD Therapy Study Fails
|